NetworkNewsBreaks – Alkermes plc (NASDAQ: ALKS) Featured in Mizuho Securities Research Report

Company: Alkermes plc (ALKS)
Category: Analyst Alerts

Alkermes plc (NASDAQ: ALKS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Alkermes announced this morning that the FDA will hold an Advisory Committee Meeting on October 9 to discuss their pipeline drug ALKS 3831. We already knew a meeting was coming up ahead of the November 15 FDA action date and that it would focus on the clinical meaningfulness of the ALKS 3831 data. Importantly, the company also now disclosed that the meeting will discuss “”certain potential clinical risks related to the interaction of ALKS 3831…and opioids in the intended patient populations””. We believe most investors are assuming an on-time approval of ALKS 3831. Today’s disclosure raises some questions on that, and we believe may lead to some pressure on the stock.”

To request access to the full report, visit http://nnw.fm/SaZ9d

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, visit the company’s website at www.Alkermes.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000